FDA Lowers the Bar for What Counts as Orange Juice
Published Date: 7/20/2026
Rule
Summary
The FDA is updating the rules for pasteurized orange juice by lowering the minimum sugar content and allowing up to 15% of a new type of citrus juice. This change helps juice makers, especially in Florida, keep up with modern practices without raising costs. The new rules kick in on August 19, 2026, giving producers time to adjust.
Analyzed Economic Effects
4 provisions identified: 4 benefits, 0 costs, 0 mixed.
Permit up to 15% Citrus reticulata juice
The FDA increases the maximum allowable volume of unfermented Citrus reticulata (or hybrids) in pasteurized orange juice from 10 percent to 15 percent. After this change, pasteurized orange juice must be at least 85 percent Citrus sinensis by volume if Citrus reticulata is used.
Manufacturers estimated cost savings ~$28M/year
FDA estimates primary annualized cost savings to manufacturers of about -$28.8 million at a 3% discount rate and about -$28.4 million at a 7% discount rate, annualized over 10 years, from the added flexibility to use lower-Brix fruit and different blends.
Minimum sugar standard lowered to 10° Brix
The FDA lowers the minimum soluble solids (Brix) for pasteurized orange juice from 10.5° to 10° Brix. This changes sugar per 8-ounce serving from about 18 grams to about 17 grams and alters some nutrients (potassium 455→419 mg per serving, folate 96→89 µg DFE per serving, vitamin C 74→85 mg per serving). FDA says these differences are small and unlikely to materially affect taste or nutrition.
No new labeling or compliance burdens
FDA states the final rule does not change any labeling requirements for pasteurized orange juice: grams of sugar remain on the Nutrition Facts label, and FDA declined to require Brix disclosure. FDA also concludes the rule does not impose compliance costs on industry.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-18023, Determination That PHENAPHEN WITH CODEINE NO. 3 (Acetaminophen; Codeine Phosphate) Oral Capsules, 325 Milligrams and 30 Milligrams, and PHENAPHEN WITH CODEINE NO. 4 (Acetaminophen; Codeine Phosphate) Oral Capsules, 325 Milligrams and 60 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The Food and Drug Administration (FDA or Agency) has determined that PHENAPHEN WITH CODEINE NO. 3 (acetaminophen; codeine phosphate) oral capsules, 325 milligrams (mg) and 30 mg, and PHENAPHEN WITH CODEINE NO. 4 (acetaminophen; codeine phosphate) oral capsules, 325 mg and 60 mg, were not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for PHENAPHEN WITH CODEINE NO. 3 (acetaminophen; codeine phosphate) oral capsules, 325 mg and 30 mg, and PHENAPHEN WITH CODEINE NO. 4 (acetaminophen; codeine phosphate) oral capsules, 325 mg and 60 mg, if all other legal and regulatory requirements are met.
2026-17968, Determination That CARAFATE (Sucralfate) Oral Suspension, 1 Gram/10 Milliliters, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The Food and Drug Administration (FDA, Agency, or we) has determined that CARAFATE (sucralfate) oral suspension, 1 gram (g)/10 milliliters (mL), was not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to this drug product, and it will allow FDA to continue to approve ANDAs that refer to the product as long as they meet relevant legal and regulatory requirements.
2026-17961, Pharmacokinetics in Patients With Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosage; Draft Guidance for Industry; Availability
The Food and Drug Administration (FDA) is announcing the availability of a draft guidance for industry titled "Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosage." This guidance assists sponsors in the design and analysis of studies that assess the influence of hepatic impairment on the pharmacokinetics and, where appropriate, the pharmacodynamics of a drug, including therapeutic biological products. When final, this guidance will represent FDA's current thinking. FDA is also withdrawing the guidance for industry titled "Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling" (May 2003), which formerly provided FDA's thinking relating to studies to assess the effect of hepatic impairment on the pharmacokinetics or pharmacodynamics of a drug and recommendations to include hepatic impairment information in labeling.
Previous / Next Documents
Previous: 2026-14553, 2026 Quarterly Listings: First Quarter; Safety Zones, Security Zones, and Special Local Regulations
The Coast Guard is letting everyone know about temporary safety and security rules that were active in early 2026 but expired before they could be officially published. These rules affect boaters, event organizers, and waterfront businesses by setting up safety zones and special event regulations to keep everyone safe. While these rules didn’t cost money or last long, they helped protect people and property during emergencies and special events.
Next: 2026-14578, Takes of Marine Mammals Incidental to Specified Activities; Taking Marine Mammals Incidental to Texas Parks and Wildlife Department Fisheries Research
The Texas Parks and Wildlife Department got the green light to continue their fisheries research in Texas coastal bays for the next five years, even if it means accidentally disturbing some marine mammals. New rules make sure they do this carefully, with strict monitoring and reporting to protect these animals and their homes. This starts August 1, 2026, and keeps science and sea life safe without extra costs to the public.